Novel broadly neutralizing antibodies targeting HIV-1 hold promise for their use in the prevention and treatment of HIV-1 infection. Pre-clinical results have encouraged the evaluation of these antibodies in healthy and HIV-1-infected humans. In first clinical trials, highly potent broadly neutralizing antibodies have demonstrated their safety and significant antiviral activity by reducing viremia and delaying the time to viral rebound in individuals interrupting antiretroviral therapy. While emerging antibody-resistant viral variants have indicated limitations of antibody monotherapy, strategies to enhance the efficacy of broadly neutralizing antibodies in humans are under investigation. These include the use of antibody combinations to prevent viral escape, antibody modifications to increase the half-life and the co-administration of latency-reversing agents to target the cellular reservoir of HIV-1. We provide an overview of the results of pre-clinical and clinical studies of broadly HIV-1 neutralizing antibodies, discuss their implications and highlight approaches for the ongoing advancement into humans.

中文翻译：

---

抗体介导的 HIV-1 感染预防和治疗

针对 HIV-1 的新型广泛中和抗体有望用于预防和治疗 HIV-1 感染。临床前结果鼓励在健康人和 HIV-1 感染者中对这些抗体进行评估。在首次临床试验中，高效广泛中和抗体通过减少中断抗逆转录病毒治疗的个体的病毒血症和延迟病毒反弹时间，证明了其安全性和显着的抗病毒活性。虽然新出现的抗体抗性病毒变种表明抗体单一疗法的局限性，但增强人类广泛中和抗体功效的策略正在研究中。其中包括使用抗体组合来防止病毒逃逸、修饰抗体以延长半衰期以及共同施用潜伏期逆转剂来靶向 HIV-1 的细胞库。我们概述了广泛的 HIV-1 中和抗体的临床前和临床研究结果，讨论了它们的影响，并重点介绍了持续进展到人类的方法。